The Aerogen Pro can be cleaned, disinfected, and sterilized. Always clean, disinfect or sterilize in accordance with the current hospital protocols. Please see the Aerogen Pro Instruction manual for more information21.
The Aerogen Pro system is designed to be reusable and the nebuliser is expected to last for approximately 1 year of a typical usage of 4 treatments per day and one sterilization per week where the device is assumed to be used for 50% of the time. Refer to your local distributor regarding warranty details.
In order to remove any residues of viscous drugs you can nebulise a few drops of saline.
The Aerogen Pro can be used with any brand or model of ventilator.
Medication left in the nebuliser at the end of the treatment is minimal: < 0.1ML21.
The medication cup can hold up to 10mL of medication.
The flow rate of the Aerogen Pro is > 0.2ml/min with an average of 0.4ml/min. For a standard 3ml dose this would therefore take 7 minute 30 seconds21.
You don’t need a different Aerogen Pro to nebulise different drugs but when nebulising viscous drugs you may need to add a few drops of saline to clear the mesh before nebulising the next drug. Always refer to the drug manufacturer’s guidelines before combining drugs for nebulisation.
The Aerogen Pro can be used to nebulise all physician prescribed drugs approved for use with a general purpose nebuliser. Aerogen Ltd cannot provide specific advice on medication dose as it does not have regulatory approvals for drug/device combinations at this time. Information on drug dosing with specific nebulisers must be sourced from the manufacturer’s approved prescribing information for the inhaled formulation, bearing in mind published clinical research examining the efficiency of the different nebuliser technologies in terms of delivering therapeutic/effective drug levels in the lungs for specific medications. Should you require information regarding published clinical research for nebulisation of specific medications with Aerogen’s devices then please contact our Clinical team directly at firstname.lastname@example.org (US)/Canada or email@example.com (Rest of world).
It is recognised that physicians prescribe medications for nebulisation that are not approved for use with a general purpose nebuliser based on their perceived clinical need and the risk: benefit ratio for the patient. This is classified as ‘off label’ use of those products and Aerogen Ltd cannot and does not promote ‘off label’ use of its devices.
Yes, the Aerogen Pro can be connected to a mouthpiece using the adult T-piece. An aerosol mask can be connected by using the vented elbow and face mask elbow which are provided in the Aerogen Pro mask kit. Masks and mouthpieces are not included.
The Aerogen Pro is virtually silent. The noise level is less than 35dB measured at 0.3m distance.
The Aerogen Pro provides improved drug dose compared to standard jet nebuliser during mechanical ventilation1 and NIV18.
Contact your local Aerogen Pro Distributor.
1. Ari A, Areabi H, Fink JB, Cpft PT, Areabi H, Rrt M et al. Evaluation of aerosol generator devices at 3 locations in humidified and non-humidified circuits during adult mechanical ventilation. Respir Care 2010; 55: 837–844. 2. Lin HL, Fink JB, Zhou Y, Cheng YS. Influence of moisture accumulation in inline spacer on delivery of aerosol using metered-dose inhaler during mechanical ventilation. Respir Care 2009; 54: 1336–1341. 3. Kaminsky DA, Bates JH, Irvin CG. Effects of cool, dry air stimulation on peripheral lung mechanics in asthma. Am J Respir Crit Care Med 2000; 162: 179–186. 4. Saeed H, Abdelrahim MEA, Fink JB. Stability of commonly nebulised drugs in heated and humid condition. Med Sci 2018; 7: 269–76. 5. Ari A, Atalay OT, Harwood R, Sheard MM, Aljamhan EA, Fink JB. Influence of nebuliser type, position, and bias flow on aerosol drug delivery in simulated paediatric and adult lung models during mechanical ventilation. Respir Care 2010; 55: 845–851. 6. Berlinski A, Willis JR. Albuterol delivery by 4 different nebulisers placed in 4 different positions in a paediatric ventilator in vitro model. Respir Care 2013; 58: 1124–1133. 7. Ari A, Fink JB. Aerosol Drug Delivery During Mechanical Ventilation: Devices, Selection, Delivery Technique, and Evaluation of Clinical Response to Therapy. Clin Pulm Med 2015; 22: 79–86. 8. Reminiac F, Vecellio L, Loughlin RM, Le Pennec D, Cabrera M, Vourc’h NH et al. Nasal high flow nebulisation in infants and toddlers: An in vitro and in vivo scintigraphic study. Pediatr Pulmonol 2017; 52: 337–344. 9. Li J, Gong L, Ari A, Fink JB. Decrease the flow setting to improve trans‐nasal pulmonary aerosol delivery via “high‐flow nasal cannula” to infants and toddlers. Pediatr Pulmonol 2019; : ppul.24274. 10. Aerogen Solo System Instruction Manual. Aerogen Ltd. P/N 30-354, Part No. AG-AS3050. 11. Alcoforado L, Ari A, De Melo Barcelar J, Brandao SS, Fink JB, Dornelas De Andrade A. Comparison of Aerosol Deposition with Heated and Unheated High Flow Nasal Cannula (HFNC) in Healthy Adults. Poster Present ATS 2016. 12. Reminiac F, Vecellio L, Bodet-Contentin L, Gissot V, Le Pennec D, Salmon Gandonniere C et al. Nasal high-flow bronchodilator nebulisation: a randomized cross-over study. Ann Intensive Care 2018; 8: 128. 13. Dhand R. Basic techniques for aerosol delivery during mechanical ventilation. Respir Care 2004; 49: 611– 22. 14. Berlinski A, Willis JR. Effect of Tidal Volume and Nebuliser Type and Position on Albuterol Delivery in a Paediatric Model of Mechanical Ventilation. Respir Care 2015; 60: 1424–1430. 15. Dugernier J, Reychler G, Wittebole X, Roeseler J, Depoortere V, Sottiaux T et al. Aerosol delivery with two ventilation modes during mechanical ventilation: a randomized study. Ann Intensive Care 2016; 6: 73. 16. MacIntyre NR, Silver RM, Miller CW, Schuler F, Coleman RE. Aerosol delivery in intubated, mechanically ventilated patients. Crit Care Med 1985; 13: 81–84. 17. Galindo-Filho VC, Ramos ME, Rattes CS, Barbosa AK, Brandao DC, Brandao SCS et al. Radioaerosol Pulmonary Deposition Using Mesh and Jet Nebulisers During Noninvasive Ventilation in Healthy Subjects. Respir Care 2015; 60: 1238–1246. 18. Dugernier J, Hesse M, Vanbever R, Depoortere V, Roeseler J, Michotte JB et al. SPECT-CT Comparison of Lung Deposition using a System combining a Vibrating-mesh Nebuliser with a Valved Holding Chamber and a Conventional Jet Nebuliser: a Randomized Cross-over Study. Pharm Res 2017; 34: 290–300. 19. Abdelrahim ME, Plant P, Chrystyn H. In-vitro characterisation of the nebulised dose during non-invasive ventilation. J Pharm Pharmacol 2010; 62: 966–972. 20. Berlinski A, Velasco J. Albuterol Delivery Efficiency in a Paediatric Model of Noninvasive Ventilation With a Single-Limb Circuit. Respir Care 2019; : respcare.06622. 21. Velasco J, Berlinski A. Albuterol Delivery Efficiency in a Paediatric Model of Noninvasive Ventilation With Double-limb Circuit. Respir Care 2018; 63: 141–146. 22. Berlinski A, Kumaran S. Particle Size Characterization of Nebulised Albuterol Delivered by a Vibrating Mesh Nebuliser Through Paediatric Endotracheal Tubes. POster Present ATS 2016. 23. Dubus JC, Vecellio L, De Monte M, Fink JB, Grimbert D, Montharu J et al. Aerosol deposition in neonatal ventilation. Pediatr Res 2005; 58: 10–14. 24. Ní Mhurchú Sorcha, Brady Paul, McKenna Cathy, Bennett Gavin , Joyce Mary, Sweeney Louise MR. Effect of Nebuliser Position on Aerosol Delivery during Mechanical Ventilation of a Neonate. Irish Thorac Soc poster 2018. 25. Ari A, Fink JB, de Andrade AD, AlHamad B, Sheard M, AlHamad B et al. Performance Comparisons of Jet and Mesh Nebulisers Using Different Interfaces in Simulated Spontaneously Breathing Adults and Children. J Aerosol Med Pulm Drug Deliv 2015; 28: 281–289. 26. Ari A, Pt R, Faarc C, Restrepo RD, Faarc R. AARC Clinical Practice Guideline Aerosol Delivery Device Selection for Spontaneously Breathing Patients: 2012. 2012. doi:10.4187/respcare.01756. 27. Aerogen Pro System Instruction Manual. Aerogen Ltd. Part No. AG-AP1080 P/N 30-040. Aerogen Ltd.